There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate rates of serious organ specific immune-related adverse events, general
adverse events related to immune activation, and adverse events consistent with musculoskeletal
problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control
treatments.